Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Drug name
Type
1 0
1 0
1 0
1 0
0 1
0 1
0 1
0 1
Serologic HistologicALAT LEVELS ENHANCED 1 0
STEATOSIS ENHANCED 1 0
BALLONNING ENHANCED 0 0
LOBULAR INFLAMMATION ENHANCED 0 0
PORTAL INFLAMMATION ENHANCED 0 0
ON NAS SCORE >=4 0 0
NAS SCORE ENHANCED BY MIN 2 POINTS 1 0
NASH REVERSION WITHOUT WORSENING OF FIBROSIS 1 0
FIBROSIS SCORE ENHANCED 0 0
OTHER BENEFITS 0 0
WEIGHT LOSS 1 0
LIPIDIC PROFILE ENHANCED 0 0
INSULIN SENSITIVITY ENHANCED 1 0
NAS SCORE Yes NoNAFLD 0 1
NAS 3 1 0
NAS 4 1 0
NAS 5 1 0
NAS 6 1 0
NAS 7 1 0
NAS 8 1 0
FIBROSIS SCORE Yes NoF0 - NO FIBROSIS 1 0
F1 1 0
F2 1 0
F3 1 0
F4 - CIRRHOSIS 1 0
PATIENTS WITH CARDIOVASCULAR RISK Yes NoEXCLUSION 0 1
INCLUSION 1 0
PATIENTS WITH T2 DIABETES Yes NoEXCLUSION 0 1
INCLUSION 1 0
© G.DIVRY 2015 -‐ WWW.NASHBIOTECHS.COM
TARGETED MARKET CRITERIAS TARGETED NASH MARKET SEGMENTS AND SIZE
GRANITE LIKE AREA ARE EXCLUDED MARKET SEGMENTS
CONFIDENCE IN SUCCESS POSOLOGY1,8mg
Once a day
ANOREXIA 0
SUBCUTANEOUS 1
PRURIT#REF!
PER OS 0
LIPIDIC PROFILE WORSENED 0
INTRAVENOUS 0
INSULIN SENSIVITY WORSENED 0
INTRAMUSCULAR 0
NO WORSENING OF FIBROSIS
CLINICAL STUDIES RESULTS
#
ADVERSE EFFECTS ADMINISTRATION MODE
Serious or Moderate
OTHER TREATMENT STABILIZED
PROVED DOSE/EFFECT RELATIONSUBPART H ELIGIBLE
0NASH REVERSION CRITERIA
SEROLOGICAL CRITERIAS
HISTOLOGIC CRIT ON STARTFAST TRACK
0HISTOLOGIC CRIT AT END
CENTRALIZED READING BREAKTHROUGH THERAPY
0
glukagon like peptide
CLINICAL STUDIES AVANCEMENT STUDIES RELEVANCE FDA STATUS
NASH BIOTECH OVERVIEW NOVO NORDISKVICTORZA
7%
7%
8%
10%
2%
5%
5%
6% 8%
2%
5%
2%
3%
3%
1%
6%
5%
6%
7% 2%
MARKET �ESTIMED SIZE �
Billions $ � 31,1 �